Related Experiment Video
Updated: Mar 15, 2026
Database-guided Flow-cytometry for Evaluation of Bone Marrow Myeloid Cell Maturation
Published on: November 3, 2018
[Predictive molecular pathological stratification of hematological neoplasms]
1Institut für Pathologie, Universitätsklinikum Ulm, Albert-Einstein-Allee 11 (M23), 89070, Ulm, Deutschland. mindaugas.andrulis@uniklinik-ulm.de.
Abstract:
The comprehensive sequencing of the complete genome of various hematological neoplasms has allowed an in-depth insight into the genomic heterogeneity and led to the discovery of new genetic aberrations, which seem to be very promising as therapeutic target structures. The molecular target structures of new therapeutic agents are, however, nearly exclusively proteins and cannot be directly identified with nucleic acid-based investigation methods. There is a great potential in investigations at the protein level that reflect an expression of the target protein and/or alterations of the signal cascade in tumor cells. In this context immunohistochemistry is a procedure that can deliver the decisive information using mutation, phosphorylation and glycosylation-specific primary antibodies. This study was carried out to comprehensively investigate the diagnostic utilization of such antibodies for hematological neoplasms. The studies summarized in this article emphasize the significance of tissue-based diagnostic approaches at the protein level and are suitable for use in patient selection for targeted treatment. A particular success of these studies was to make an essential contribution to the predictive diagnostics of multiple myeloma.
Insights
Protein-based diagnostics using immunohistochemistry are crucial for identifying therapeutic targets in hematological neoplasms. This approach aids in selecting patients for targeted treatments, particularly advancing predictive diagnostics for multiple myeloma.
Area of Science:
- Hematology
- Oncology
- Molecular Biology
Background:
- Genomic sequencing reveals heterogeneity and potential therapeutic targets in hematological neoplasms.
- Current targeted therapies primarily focus on protein targets, which are not directly detectable by nucleic acid methods.
- Protein-level analysis offers insights into target expression and signaling pathways in tumor cells.
Purpose of the Study:
- To investigate the diagnostic utility of protein-specific antibodies in hematological neoplasms.
- To highlight the importance of tissue-based protein diagnostics for patient selection in targeted therapy.
- To assess the contribution of these methods to the predictive diagnostics of multiple myeloma.
Main Methods:
- Utilizing immunohistochemistry with mutation, phosphorylation, and glycosylation-specific primary antibodies.
- Analyzing protein expression and alterations in signal cascades within tumor cells.
- Evaluating diagnostic applications for various hematological neoplasms.
Main Results:
- Demonstrated the diagnostic value of protein-level investigations in hematological malignancies.
- Confirmed the suitability of immunohistochemistry for identifying therapeutic targets.
- Showcased significant contributions to the predictive diagnostics of multiple myeloma.
Conclusions:
- Tissue-based protein diagnostics are essential for effective patient selection in targeted cancer therapy.
- Immunohistochemistry provides critical information for identifying actionable protein targets in hematological neoplasms.
- This approach significantly enhances the predictive diagnostics for multiple myeloma and other related cancers.
